{
    "Trade/Device Name(s)": [
        "Buprenorphine Urine Test",
        "Oxycodone Urine Test",
        "Wondfo Buprenorphine Urine Test",
        "Wondfo Oxycodone Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K113624",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060466",
        "K033047"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "February 22, 2012",
    "Summary Letter Received Date": "February 27, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Buprenorphine",
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup",
        "Dip card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry",
        "Lateral flow immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Buprenorphine and Oxycodone Urine Test for qualitative detection of respective analytes in human urine using immunochromatographic lateral flow technology",
    "Indications for Use Summary": "Wondfo Buprenorphine Urine Test: qualitative detection of buprenorphine in human urine (prescription use only); Wondfo Oxycodone Urine Test: qualitative detection of oxycodone in human urine (OTC and prescription use); both are in vitro diagnostic and provide only preliminary test results requiring confirmation.",
    "fda_folder": "Toxicology"
}